Targeted imaging BioLaurus specializes in preclinical molecular imaging with capabilities across PET, SPECT, CT, MRI, Ultrasound, FLI, and BLI, presenting a strong value proposition for pharma and biotech clients needing comprehensive imaging for PoC, efficacy, safety pharmacology, and MOA studies.

Flexible partnerships The company emphasizes partnering and integrating with client operations to the extent desired, offering study design, RFQ writing, outsourcing, monitoring, analysis, and reporting, which can be pitched as scalable collaboration models for mid to late-stage research contracts.

Specialized domains Recent focus areas include NASH, mu-opioid receptor studies, and platelet sequestration PK, enabling targeted outreach to biopharma companies active in liver fibrosis, pain management, and hematology/metabolic disorder pipelines.

Emerging ultrasound Applied ultrasound methods to measure NASH in mouse models signal capability in non-invasive imaging modalities, offering a differentiator for preclinical safety and fibrosis research collaborations and potential IP or method development opportunities.

Strategic partnerships Historical collaboration with BTS Research and published development efforts heighten credibility for joint ventures and co-development projects, suggesting open doors for channel partners, CROs, and contract research alliances seeking imaging expertise.